We show that we can optimally mature patient-derived DCs in vitro with tumour-specific lysate, Ampligen®, an IFN-containing cocktail (IFN-α, IFN-γ, IL-1β, CD40L) and R848. Here, IFNA1 is linked to neoplasm.